vibsanin-a and Leukemia--Myeloid--Acute

vibsanin-a has been researched along with Leukemia--Myeloid--Acute* in 1 studies

Other Studies

1 other study(ies) available for vibsanin-a and Leukemia--Myeloid--Acute

ArticleYear
Vibsanin A sensitizes human acute myeloid leukemia cells to tyrosine kinase inhibitor-induced myeloid differentiation via activation of PKC and upregulation of Lyn.
    Biochemical and biophysical research communications, 2018, 07-07, Volume: 502, Issue:1

    Differentiation therapies have been proposed to overcome the impaired cell differentiation in acute myeloid leukemia (AML). However, thus far the all-trans retinoic acid-based differentiation therapy has been the only successful modality in treating acute promyelocytic leukemia. Here, we showed that vibsanin A, a novel protein kinase C (PKC) activator, sensitized AML cells to tyrosine kinase inhibitor (TKI)-induced differentiation. Vibsanin A augmented the ability of TKIs to induce growth inhibition and G1 cell cycle arrest of AML cells. Mechanistically, PKC activation was involved in the differentiation-inducing effects of combining vibsanin A with TKIs. Moreover, we found that vibsanin A enhanced TKI-induced Lyn expression and suppression of Lyn interfered with AML cell differentiation, indicating an essential role for Lyn expression in the combination-induced differentiation. Finally, combining vibsanin A and TKIs enhanced the activation of the Raf/MEK/ERK cascade. Together, this is the first study to evaluate the synergy of vibsanin A and TKIs in AML cell differentiation. Our study lays the foundation in assessing new opportunities for the combination of vibsanin A and TKIs as a promising approach for future differentiation therapy.

    Topics: Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Diterpenes; Enzyme Activators; Humans; Leukemia, Myeloid, Acute; Myeloid Cells; Protein Kinase C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; src-Family Kinases

2018